A practical reference on receptor agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-03. Anything still debated is marked as such rather than presented as settled.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
| Property | Value | Notes |
|---|---|---|
| Molecular class | 31-amino-acid peptide | Modified glucagon-like peptide-1 analogue |
| Molecular mass | approximately 4114 Da | Calculated for the free peptide backbone |
| Appearance | white to off-white powder | Typical of purified lyophilised peptide batches |
| Solubility class | freely soluble in water | Aqueous solubility improves at slightly alkaline pH |
| Typical storage | -20 degrees Celsius, dry, dark | Protect from repeated freeze-thaw cycles |
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
Quantification and purity assessment rely on separation methods coupled to optical or mass detection. Reversed-phase high-performance liquid chromatography resolves the intact peptide from related impurities and is the standard assay technique. Size-exclusion chromatography measures aggregates, while ion-exchange chromatography separates charge variants produced by deamidation. Mass spectrometry confirms identity and detects mass shifts of a few daltons. In biological matrices, liquid chromatography with tandem mass spectrometry is often used because immunoassays can cross-react with endogenous GLP-1 or with circulating fragments.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
市售注射用制剂通常要求在二至八摄氏度冷藏保存，并避免光照与冻结。部分多剂量笔在首次使用后允许在不超过三十摄氏度的环境中存放有限周数，具体期限由辅料与防腐剂体系决定。反复冻融会促进肽链聚集并改变可见颗粒计数，因此应予避免。冻干粉末在干燥、避光、低温条件下更为稳定。溶液配制后宜使用低吸附容器，以减少肽类在塑料或玻璃表面的损失。
纯度评价多采用反相高效液相色谱，流动相常加入三氟乙酸或甲酸作为离子对改性剂，检测波长设在二百一十四纳米或二百二十纳米。分子量确认依靠电喷雾电离质谱或基质辅助激光解吸电离质谱，实测值应与理论值在数 ppm 内吻合。肽图分析通过酶切后液相色谱串联质谱完成，用于核查序列与修饰位点。体积排阻色谱用于定量共价与非共价聚集体。生物基质浓度测定则采用免疫分析或液相色谱串联质谱。
== Pharmacology == Akuammine has antimalarial activity, and may be the primary constituent of P. nitida seeds responsible for this activity. Akuammine is an opioid agonist with low affinity, selective for the mu-opioid receptor, when tested in vitro.
Penicillium expansum is a psychrophilic blue mold that is common throughout the world in soil. It causes Blue Mold of apples, one of the most prevalent and economically damaging post-harvest diseases of apples. Though primarily known as a disease of apples, this plant pathogen can infect a wide range of hosts, including pears, strawberries, tomatoes, corn, and rice. Penicillium expansum produces the carcinogenic metabolite patulin, a neurotoxin that is harmful when consumed. Patulin is produced by the fungus as a virulence factor as it infects the host. Patulin levels in foods are regulated by the governments of many developed countries. Patulin is a particular health concern for young children, who are often heavy consumers of apple products. The fungus can also produce the mycotoxin citrinin.
DNA-binding protein (DBP) Any polypeptide or protein containing one or more domains capable of interacting chemically with one or more parts of a DNA molecule, and consequently having a specific or general affinity for single- and/or double-stranded DNA. DNA-binding activity often depends on the presence and physical accessibility of a specific nucleobase sequence, and mostly occurs at the major groove, since it exposes more of the functional groups which uniquely identify the bases. Binding is also influenced by the spatial conformation of the DNA chain and the occupancy of other proteins near the binding site; many proteins cannot bind to DNA without first undergoing conformational changes induced by interactions with other molecules.
=== Sanger's rule === ... anytime you get technical development that's two to threefold or more efficient, accurate, cheaper, a whole range of experiments opens up. This rule should not be confused with Terence Sanger's rule, which is related to Oja's rule.
Sources: en.wikipedia.org
== Applications == Freeze-drying (lyophilization) cycle development and optimization for pharmaceuticals. Flow diagnostics in hypersonic/re-entry speed research facilities and scramjet combustors. Oxygen tunable diode laser spectrometers play an important role in safety applications in a wide range of industrial processes, for this reason, TDLS are often an integral part of modern chemical plants. The fast response time compared to other technologies for measuring gas composition, and the immunity to many background gasses and environmental conditions makes TDL technology a commonly selected technology for monitoring of combustible gasses in process environments. This technology is employed on flares, in vessel headspace and in other locations where explosive atmospheres must be prevented from forming. According to a 2018 research study, TDL technology is the 4th most commonly selected technology for gas analysis in Chemical Processing.
== Smart insulin pen compatibility == A smart insulin pen is a reusable injector pen designed to assist people with diabetes in managing insulin delivery more effectively. This system is paired with a smartphone app that calculates and tracks insulin doses, providing reminders, alerts, and reports to ensure better diabetes management. Some smart insulin pens are capable of integrating with Dexcom continuous glucose monitoring data, enabling users to make more informed decisions based on real-time glucose levels. These pens can be either an add-on to an existing insulin pen or a standalone reusable device that uses prefilled cartridges instead of vials or disposable pens.
In order to successfully complete their folding, both actin and tubulin need to interact with another protein called prefoldin, which is a heterohexameric complex (formed by six distinct subunits), in an interaction that is so specific that the molecules have coevolved. Actin forms a complex with prefoldin while it is still being formed, when it is approximately 145 amino acids long, specifically those at the N-terminal. Different recognition sub-units are used for actin or tubulin although there is some overlap. In actin the subunits that bind with prefoldin are probably PFD3 and PFD4, which bind in two places one between residues 60–79 and the other between residues 170–198. The actin is recognized, loaded, and delivered to the cytosolic chaperonin (CCT) in an open conformation by the inner end of prefoldin's "tentacles" (see the image and note). The contact when actin is delivered is so brief that a tertiary complex is not formed, immediately freeing the prefoldin.
Sources: en.wikipedia.org
=== Pharmacodynamics === Dimethocaine and structurally related local anesthetics such as cocaine and procaine inhibit the uptake of dopamine (DA) by blocking dopamine transporters (DAT). The dopamine transporter controls the dynamics of the neurotransmitter dopamine. This neurotransmitter controls many functions including movement, cognition and mood. Drugs such as cocaine and dimethocaine induce dopamine overflow by inhibiting dopamine transporters and thus creating a euphoric effect. In addition to inhibiting dopamine uptake, dimethocaine was also shown to inhibit the binding of CFT, a different dopamine uptake inhibitor. These inhibitory properties are responsible for the stimulatory effects of dimethocaine on the central nervous system. Both in vivo and in vitro measurements of dopamine transporter activity showed that dimethocaine is a potent and efficacious dopaminergic reuptake inhibitor (also called a dopamine indirect agonist). These effects were mainly observed in the nucleus accumbens, a region in the basal forebrain. Comparison of the pharmacological potencies of different local anesthetics revealed the following potency order: cocaine > dimethocaine > tetracaine > procaine > chloroprocaine Furthermore, the administration of dimethocaine has been shown to lead to antinociceptive responses at nontoxic doses in mice. These responses are suggested to be at least partially caused by the effects of dimethocaine on the central nervous system.
12 July – NASA releases the first suite of images from the now fully operational James Webb Space Telescope, a day after releasing the Webb's First Deep Field, the image of early universe with the highest resolution. On 14 July, NASA presents images of Jupiter and related areas captured, for the first time, and including infrared views, by the telescope. On 19 July, scientists report what could be the earliest and most distant galaxy ever discovered, GLASS-z12. 13 July The discovery of fast radio burst FRB 20191221A with an unusually long duration of three seconds is reported. A study affirms (see 7 March) that critical slowing down indicators suggest that tropical, arid and temperate forests are substantially losing resilience. On 4 July, Brazil's INPE reports that the country's regions of the Amazon rainforest have been deforested by a record amount in the first half of 2022. A study shows that blood cells' loss of the Y chromosome in a subset of cells, reportedly affecting at least 40% of 70 years-old men to some degree, contributes to fibrosis, heart risks, and mortality in a causal way. Researchers report the development of semitransparent solar cells that are as large as windows, after team members achieved record efficiency with high transparency in 2020. On 4 July, researchers report the fabrication of solar cells with a record average visible transparency of 79%, being nearly invisible.
In his (August 1962) Report to the National Research Council of the National Academy of Sciences (AP.2), Archie Palmer reported that, of the 945 US "higher education institutions" he had surveyed, 349 had either "formulated and adopted a formalized research and patent policy", or were observing "a generally accepted practice with respect to the handling of research and patent matters", whilst the remaining 596 (which, he observed, conducted "little or no scientific or technological research") had "no formalized research or patent policies". In 1965, 96 US patents were granted to 28 "US universities or related institutions"; in 1992, 1500 US patents were granted to more than 150 "US universities or related institutions" (RH.2, p. 119). In 2025, the (formerly reluctant) University of California had been granted 571 patents, making the university's total "over 6,800 active patents" (JB.1). According to the economists Stanley Engerman and Gavin Wright (SE.1), (a) until 1933 there were more US patents issued to individuals than those issued to corporations, (b) by 1950 the ratio was 50:50, (c) by 1998, whilst the number of US patents issued to individual inventors remained more or less the same, (i.e., 10,000–15,000 per annum), they only represented approx. 10% of the number of patents issued.
Sources: en.wikipedia.org
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.
No. It shares high sequence identity but carries non-natural modifications that alter its stability and clearance. The naturally occurring hormone is broken down within minutes, while the synthetic analogue circulates far longer.
Attachment to serum albumin reduces renal filtration of the peptide and shields it from enzymatic breakdown. The consequence is a much longer interval between administrations than unmodified peptides allow. The precise contribution of binding affinity to overall duration is still being quantified.
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.